Tech Transfer Roundup: Amgen Teams With MD Anderson To Accelerate Early-Stage Cancer Candidates

In a busy month, MD Anderson also partners with Ipsen on an unspecified cancer drug and licenses poziotinib IP to...

More From BioPortfolio on "Tech Transfer Roundup: Amgen Teams With MD Anderson To Accelerate Early-Stage Cancer Candidates"